Actavis creates newer version of Alzheimer’s treatment to combat generic competition


Actavis is looking to phase out its Namenda IR treatment for Alzheimer’s and replace it with a new treatment, called Namenda XR. Regulators have speculated that Actavis switched the treatments in order to avoid generic competition on Namenda IR, switching patients to the new drug before lower cost alternatives came to the market. The state of New York has already filed a lawsuit based on the action, claiming that Actavis violated anti-trust law.


Read the source article at WSJ Blogs

About the Author

Related Posts

Leave a Reply